Check out the new publication in New England Journal of Medicine
https://www.nejm.org/doi/full/10.1056/NEJMoa1801109?query=TOC ...and fantastic news coverage: http://www.mdalert.com/news/article/poisoning-antidote-protects-against-hearing-loss-when-a-child-gets-anticancer-drug https://www.bbc.com/news/health-44546323
.		 ANNOUNCEMENTS

Virtual Consultation System to support Clinicians

We would like to encourage you to use a new open service of online consultations for your cases of pediatric liver tumors.

The platform allows for uploading radiology and pathology images and offers a coordinated advice from the top level experts representing three major international liver tumor study groups: Children Oncology Group (COG), Japanese Pediatric Liver Tumours Group (JPLT) and SIOPEL (International Childhood Liver Tumours Strategy Group).

Every new user has to register in the system before the first consultation request.



E-Learning area

We would like to inform that our E-Learning area is open and accessible by all health care providers (whether SIOPEL members or not) interested in the subject of pediatric liver tumors. In order to get access please send an email to elearning_siopel@cineca.it using your institutional email address.


.

Childhood Liver Tumours Strategy Group - SIOPEL

The ultimate goal of the SIOPEL study group is to improve the prognosis and the quality of life of children affected by primary childhood liver tumors.

Primary hepatic tumours represent less than 1% of all childhood malignancies. Their frequency according to the different series is of about 0.8 - 1 case per million children less than 15 years of age per year. Hepatoblastoma (HB) is by far the commonest histological subtype of primary malignant hepatic tumours occurring in children less than 15 years of age, followed by hepatocellular carcinoma (HCC).

SIOPEL Group is composed of basic and clinical scientists coming from different European and Extra-European countries.